Company Announcements

WATERTOWN, Mass.--(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS)International Conference 2026being held May 15-20, 2026 in Orlando, Florida.

Details of the presentations are as follows:

Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial
Abstract Number: 12336
Session C96: Lung-Specific Immunity in Viral Infection: From Real-Time Host Responses to Novel Antiviral Strategies
Session Type: Mini Symposium
Date and Time: Tuesday, May 19, 2026, from2:15 PM – 2:27 PM EDT
Presenter: Christopher Harris, M.D.

Title: EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model
Poster Number: P72
Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies
Session Type: Thematic Poster Session
Date and Time: Tuesday, May 19, 2026, from11:30 AM – 1:15 PM EDT
Presenter: Yaohui Nie, Ph.D.

Title: EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma
Poster Number: P75
Session Type: Thematic Poster Session
Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies
Date and Time: Tuesday,May 19, 2026, from11:30 AM – 1:15 PM EDT
Presenter: Lisha Xu and Yang Li, Ph.D.

Further information about ATS 2026 can be found here. Presentations will be available on the Company’s website here following each presentation.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504237451/en/

Media and Investors:
Jennifer Viera
617-744-3848
jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.